Unanticipated improvement in seizure control in drug-resistant epilepsy-real world observations

被引:5
|
作者
Moloney, Patrick B. [1 ]
Costello, Daniel J. [1 ,2 ]
机构
[1] Cork Univ Hosp, Dept Neurol, Cork, Ireland
[2] Univ Coll Cork, Coll Med & Hlth, Cork, Ireland
来源
关键词
Drug-resistant epilepsy; Anti-seizure medication; Unanticipated treatment response; Rational polytherapy; QUALITY-OF-LIFE; ANTIEPILEPTIC DRUGS; ILAE COMMISSION; REMISSION; POPULATION; LACOSAMIDE; OUTCOMES; SURGERY; RELAPSE;
D O I
10.1016/j.seizure.2020.11.005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To determine the clinical features and anti-seizure medication (ASM) strategies associated with an unanticipated substantial improvement in seizure control in patients with drug-resistant epilepsy (DRE). Methods: This retrospective analysis of patients attending a tertiary care epilepsy clinic between 2008 and 2017 identified all patients with active DRE (at least 1 seizure per month for 6 months, despite treatment with 2 different ASMs). All treatment interventions were recorded from when DRE was first identified to the end of the study. The primary end points were seizure freedom or meaningful reduction in seizure frequency (greater than 75 %) sustained for at least 12 months after a treatment intervention. Results: Three hundred and twenty-two patients were included in the analysis. Overall, 10 % became seizure free following ASM adjustment and an additional 10 % had a greater than 75 % improvement in seizure control (median follow-up, 4 years). An ASM introduction was ten times more likely than an ASM dose increase to improve seizure control. Combined focal and generalized epilepsy, intellectual disability and prior treatment with more than 5 ASMs were more frequently observed in those with continued pharmacoresistance. ASM responders were more likely to have primary generalized epilepsy. Rational polytherapy (combining ASMs with different mechanisms of action) was almost ubiquitous amongst ASMs responders (95 % taking at least 2 drugs with different mechanistic targets). Of the ASM additions that heralded improved seizure control, 85 % were maintained at submaximal doses. Conclusions: This retrospective analysis of a large number of 'real-world' patients provides evidence to persist with ASM trials in DRE. Early rotation of ASMs if a clinical response is not observed at a substantial dose and rational ASM polytherapy may yield better clinical outcomes in patients with DRE, although a prospective study would need to be conducted to validate these findings.
引用
收藏
页码:60 / 65
页数:6
相关论文
共 50 条
  • [31] Impact of the reconstruction method in the localization of the seizure onset by SISCOM in drug-resistant epilepsy
    Ripoll-Batllo, A.
    Sala-Padro, J.
    Reynes-Llompart, G.
    Mora, J.
    Saldana, P.
    Falip, M.
    Picon, C.
    Gamez-Cenzano, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S302 - S302
  • [32] Evaluating the effect of calcifediol supplementation on seizure frequency in people with drug-resistant epilepsy
    Tombini, Mario
    Palermo, Andrea
    Ricci, Lorenzo
    Boscarino, Marilisa
    Flavia, Narducci
    Biagio, Sancetta
    Naciu, Anda Mihaela
    Tabacco, Gaia
    Cesareo, Roberto
    Di Lazzaro, Vincenzo
    Assenza, Giovanni
    EPILEPSY & BEHAVIOR, 2023, 145
  • [33] Automatic Seizure Onset Detection in Drug-Resistant Epilepsy: A Bayesian Optimal Solution
    Santaniello, Sabato
    Burns, Samuel P.
    Sarma, Sridevi V.
    2012 IEEE 51ST ANNUAL CONFERENCE ON DECISION AND CONTROL (CDC), 2012, : 3189 - 3194
  • [34] How Meaningful are Seizure-Fee Periods for People with Drug-Resistant Epilepsy?
    Nashef, L.
    EPILEPSIA, 2023, 64 : 1 - 2
  • [35] Evaluation of drug-resistant epilepsy
    Arroyo, S
    REVISTA DE NEUROLOGIA, 2000, 30 (09) : 881 - 886
  • [36] Defining drug-resistant epilepsy
    Kwan, Patrick
    NEUROLOGY ASIA, 2011, 16 : 67 - 69
  • [37] Drug-Resistant Epilepsy and Surgery
    Sheng, Jiyao
    Liu, Shui
    Qin, Hanjiao
    Li, Bingjin
    Zhang, Xuewen
    CURRENT NEUROPHARMACOLOGY, 2018, 16 (01) : 17 - 28
  • [38] Management of drug-resistant epilepsy
    Loizon, Marine
    Rheims, Sylvain
    PRESSE MEDICALE, 2018, 47 (03): : 234 - 242
  • [39] VIGABATRIN IN DRUG-RESISTANT EPILEPSY
    BUCHANAN, N
    MEDICAL JOURNAL OF AUSTRALIA, 1993, 159 (05) : 356 - 356
  • [40] Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy?
    Rocha, Luisa
    Lizette Frias-Soria, Christian
    Ortiz, Jose G.
    Auzmendi, Jeronimo
    Lazarowski, Alberto
    EPILEPSIA OPEN, 2020, 5 (01) : 36 - 49